HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma

Cancer Research

Volumn 70, Issue 13, 2010, Pages 5316-5325

  Xue, Yuezhen ^a   Bellanger, Sophie ^a   Zhang, Wenying ^c   Lim, Diana ^d   Low, Jeffrey ^d   Lunny, Declan ^b   Thierry, Françoise ^a  

^a Papillomavirus Regulation and Cancer   (Singapore)

^b INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^c Shanghai Changning Maternity and Infant Health Institute   (China)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 13; PARAFFIN; POLYCLONAL ANTIBODY; PROTEIN HPV16 E2; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DISEASE MARKER; E7 GENE; GENE EXPRESSION; GENE STRUCTURE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; TUMOR GENE; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION;

ANTIBODIES; ANTIBODY SPECIFICITY; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA REPLICATION; DNA-BINDING PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOHISTOCHEMISTRY; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PARAFFIN EMBEDDING; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VIRUS REPLICATION;

EID: 77954365636     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3789     Document Type: Article

References (33)

1. Spalholz BA, Yang YC, Howley PM. Transactivation of a bovine papillomavirus transcriptional regulatory element by the E2 gene product. Cell 1985;42:183-91.
2. Thierry F, Yaniv M. The BPV1-2 trans-acting protein can be either an activator or a repressor of the HPV18 regulatory region. EMBO J 1987;6:3391-7.
3. Vinokurova S, Wentzensen N, Kraus I, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008;68:307-13. (Pubitemid 351380133)
4. Ustav M, Stenlund A. Transient replication of BPV-1 requires two viral polypeptides encoded by the E1 and E2 open reading frames. EMBO J 1991;10:449-57. (Pubitemid 21905496)
5. Bechtold V, Beard P, Raj K. Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA. J Virol 2003; 77:2021-8. (Pubitemid 36110014)
6. Herdman MT, Pett MR, Roberts I, et al. Interferon-β treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 2006;27:2341-53.
7. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16 (INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84.
8. Omori M, Hashi A, Nakazawa K, et al. Estimation of prognoses for cervical intraepithelial neoplasia 2 by p16INK4a immunoexpression and high-risk HPV in situ hybridization signal types. Am J Clin Pathol 2007;128:208-17.
9. Ressler S, Scheiden R, Dreier K, et al. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma. Clin Cancer Res 2007;13:7067-72. (Pubitemid 350276889)
10. Fiedler M, Ressler S, Campo-Fernandez B, et al. Expression of the high-risk human papillomavirus type 18 and 45 E7 oncoproteins in cervical carcinoma biopsies. J Gen Virol 2005;86:3235-41. (Pubitemid 41685155)
11. Guo M, Gong Y, Deavers M, et al. Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J Clin Microbiol 2008;46:274-80.
12. Saunier M, Monnier-Benoit S, Mauny F, et al. Analysis of human papillomavirus type 16 (HPV16) DNA load and physical state for identification of HPV16-infected women with high-grade lesions or cervical carcinoma. J Clin Microbiol 2008;46:3678-85.
13. Maitland NJ, Conway S, Wilkinson NS, et al. Expression patterns of the human papillomavirus type 16 transcription factor E2 in low- and high-grade cervical intraepithelial neoplasia. J Pathol 1998;186:275-80. (Pubitemid 28494355)
14. Stevenson M, Hudson LC, Burns JE, Stewart RL, Wells M, Maitland NJ. Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraneoplasia. J Gen virol 2000;81:1825-32.
15. Blachon S, Bellanger S, Demeret C, Thierry F. Nucleo-cytoplasmic shuttling of high risk human papillomavirus E2 proteins induces apoptosis. J Biol Chem 2005;280:36088-98.
16. Bellanger S, Demeret C, Goyat S, Thierry F. Stability of the human papillomavirus type18 E2 protein is regulated by a proteasome degradation pathway through its amino-terminal transactivation domain. J Virol 2001;75:7244-51.
17. Thierry F, Demeret C. Direct activation of caspase 8 by the proapoptotic E2 protein of HPV18 independent of adaptor proteins. Cell Death Differ 2008;9:1356-63.
18. Wang TY, Chen BF, Yang YC, et al. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol 2001;32:479-86.
19. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006;110:525-41.
20. Smedts F, Ramaekers F, Robben H, et al. Changing patterns of keratin expression during progression of cervical intraepithelial neoplasia. Am J Pathol 1990;136:657-68.
21. Carrilho C, Alberto M, Buane L, David L. Keratins 8, 10, 13, and 17 are useful markers in the diagnosis of human cervix carcinomas. Hum Pathol 2004;35:546-51.
22. Kadaja M, Sumerina A, Verst T, Ojarand M, Ustav E, Ustav M. Genomic instability of the host cell induced by the human papillomavirus replication machinery. EMBO J 2007;26:2180-91. (Pubitemid 46625800)
23. Kadaja M, Isok-Paas H, Laos T, Ustav E, Ustav M. Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. PLoS Pathog 2009;5:e1000397.
24. Wang HK, Duffy AA, Broker TR, Chow LT. Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev 2009;23:181-94.
25. Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins. Virology 2009;384:324-34.
26. McLaughlin-Drubin ME, Munger K. The human papillomavirus E7 oncoprotein. Virology 2009;384:335-44.
27. Bellanger S, Blachon S, Mechali F, Bonne-Andrea C, Thierry F. High-risk but not low-risk HPV E2 proteins bind to the APC activators Cdh1 and Cdc20 and cause genomic instability. Cell Cycle 2005;4: 1608-15. (Pubitemid 41609144)
28. Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J 1997;16:504-14. (Pubitemid 27067780)
29. Hwang ES, Riese DJ, Settleman J, et al. Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. J Virol 1993;67:3720-9. (Pubitemid 23180692)
30. Dowhanick JJ, McBride AA, Howley PM. Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol 1995;69:7791-9.
31. Penrose K, McBride A. Proteasome-mediated degradation of the papillomavirus E2-TA protein is regulated by phosphorylation and can modulate viral genome copy number. J Virol 2000;74:6031-8. (Pubitemid 30412973)
32. Burnett S, Strom AC, Jareborg N, et al. Induction of bovine papillomavirus E2 gene expression and early region transcription by cell growth arrest: correlation with viral DNA amplification and evidence for differential promoter induction. J Virol 1990;64:5529-41.
33. Bellanger S, Tan CL, Nei WL, He PP, Thierry F. The human papillomavirus type 18 E2 protein is a cell cycle-dependent target of the SCFSkp2 ubiquitin ligase. J Virol 2010;84:437-44.